Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma [Seeking Alpha]
Liquidia Corporation (LQDA)
Last liquidia corporation earnings: 3/11 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
I believe shares would be much higher if not for an on-going patent battle. This trial is only tied to the use of YUTREPIA to treat PH-ILD. Liquidia appears to be a prime candidate for a takeout by large pharma. Rasi Bhadramani/iStock via Getty Images The following segment was excerpted from the Laughing Water Capital Q1 2026 Letter. Liquidia ( LQDA ) is our maker of a drug called YUTREPIA that combats Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Interstitial Lung Disease (PH-ILD). The This article was written by Quick Insights The unresolved patent case with United Therapeutics is suppressing LQDA's share price; a favorable ruling could unlock significant upside, potentially more than doubling the stock. Even with an unfavorable outcome, LQDA can continue to grow in the PAH market, providing a measure of downside protection for the stock. If adoption trends continue, YUTREPIA could achieve a revenue run rate above $1.2B by year-end, supporting
Show less
Read more
Impact Snapshot
Event Time:
LQDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LQDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LQDA alerts
High impacting Liquidia Corporation news events
Weekly update
A roundup of the hottest topics
LQDA
News
- Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Liquidia Corporation to Participate in Upcoming Investor ConferencesGlobeNewswire
- Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? [Yahoo! Finance]Yahoo! Finance
- Should Insider Stock Sale and Analyst Optimism Around Pulmonary Drugs Require Action From Liquidia (LQDA) Investors? [Yahoo! Finance]Yahoo! Finance
- Insmed: The Pipeline Is Catching Up To The Valuation [Seeking Alpha]Seeking Alpha
LQDA
Earnings
- 3/5/26 - Beat
LQDA
Sec Filings
- 4/17/26 - Form 144
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- LQDA's page on the SEC website